Factors Driving the Global Protein Engineering Market | Technavio

LONDON–(BUSINESS WIRE)–#LabEquipmentTechnavio
market research analysts forecast the global
protein engineering market
to grow at a CAGR of close to 16%
during the period 2018-2022, according to their latest report.

This market research report segments the global
protein engineering market
into the following end-users,
including pharmaceutical and biotechnology companies, academic
institutes and research laboratories, and contract research
organizations and key regions, including the Americas, APAC, and EMEA.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Save more with Technavio. Buy 2 reports and get the
third for FREE:
all Technavio’s current offers

In this report, Technavio analysts highlight the increasing incidences
of diseases to rise demand for novel protein therapeutics as a key
factor contributing to the growth of the global protein engineering

Increasing incidences of diseases to rise
demand for novel protein therapeutics

Factors such as an increase in pollution and adoption of a sedentary
lifestyle are leading to a rise in chronic diseases such as cancer,
CVDs, diabetes, and autoimmune diseases. Cancer leads to a high annual
rate of mortality, globally. Nearly 45 million people die of NCDs every
year globally, and almost 10 million of them die of cancer.

The need for novel therapeutics has increased due to the growing
incidences of chronic diseases. Protein engineering is increasingly used
to generate recombinant protein therapeutics, which can treat a variety
of diseases including cancers, autoimmune diseases, and genetic
disorders. Monoclonal antibodies are designed to target antigens found
in cancer cells, in cancer therapeutics. Many copies of that antibody
are made in the laboratory. These antibodies get attached to the cancer
cells and act as a marker for the immune system to destroy them. For
example, alemtuzumab is a monoclonal antibody against chronic
lymphocytic leukemia. Alemtuzumab binds to the CD52 antigen, which is
found in cancer cells. The antibody destroys cancer cells with the help
of immune cells. Thus, recombinant protein therapeutics boost the
immunity and help to destroy cancer cells.

According to a senior analyst at Technavio for lab
, “Protein engineering products such as monoclonal
antibodies can provide therapeutic remedies for several ailments. Hence,
the demand for monoclonal antibodies is expected to increase with the
rise of chronic and infectious diseases, thus benefiting the protein
engineering market.”

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Global protein engineering market segmentation

Of the three major end-users, the pharmaceutical and biotechnology
companies segment held the largest market share in 2017, accounting for
nearly 43% of the market. The market share for this end-user is expected
to increase by 2022. The fastest growing end-user is contract research
organizations, which will account for nearly 27% of the total market
share by 2022.

The Americas was the leading region for the global
protein engineering market
in 2017, accounting for a market
share of nearly 39%. By 2022, APAC is expected to witness the highest
growth rate of nearly 2%.


Technavio’s best deals of the month!


Technavio supports Health for All campaign on this World Health
Day with 20% savings on all reports in the Health
and Wellness
category for the entire month.




Celebrate International Astronomy Day by indulging in a whopping 30%
savings on all reports in the Space
. Offer valid from 16th April for a limited


About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200